Drug Trial Radar · NCT02998450
A Study of IMR-687 in Healthy Adult Volunteers
Last checked: Nov 20, 2026Latest source record: May 15, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
66
Actual
Start
Oct 18, 2016
Primary completion
Jul 8, 2017
Study completion Jul 8, 2017
Sponsor
- Lead sponsor
- Cardurion Pharmaceuticals, Inc.Industry
- Sponsor type
- Industry
- Collaborators
- Quintiles, Inc.; Imara, Inc.
- First posted
- Dec 20, 2016
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years, up to 55 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
The purpose of this Phase 1a, first in human, randomized, double-blind, placebo-controlled study is to evaluate the safety, tolerability, PK and PD profile of the orally administered IMR-687 in healthy adult subjects.
Conditions
- Sickle Cell Disease
- Sickle-Cell; Hb-SC
- Sickle Beta 0 Thalassemia
Interventions
IMR-687Drug
1 of 6 possible single doses administered orally following overnight fast
Placebo Oral CapsuleDrug
Placebo oral capsule with 50 mg microcrystalline cellulose in capsules identical to those used for the active pharmaceutical ingredient.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of participants with treatment emergent adverse events and serious adverse eventsTime frame: 5 Days
- Number of participants with clinically significant changes from baseline in vital signsTime frame: Baseline to Day 5
- Number of participants with clinically significant changes from baseline in physical examinationTime frame: Baseline to Day 5
- Number of participants with clinically significant changes from baseline in hematology, chemistry, coagulation and urinalysis laboratory valuesTime frame: Baseline to Day 5
- Number of participants with clinically significant changes from baseline in 12-lead ECG parametersTime frame: Baseline to Day 2
- Use of concomitant medications and therapies, medication type and frequencyTime frame: 5 Days
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Quintiles
Overland Park, Kansas
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.